Statins for treatment of chronic liver disease.

Published on May 1, 2021in Current Opinion in Gastroenterology3.225
· DOI :10.1097/MOG.0000000000000716
Mohamad Kareem Marrache (MUSC: Medical University of South Carolina), Don C. Rockey75
Estimated H-index: 75
Sources
Abstract
PURPOSE OF REVIEW Statins are a class of lipid lower medications used primarily in patients with high-risk cardiovascular disease. Since their development, statins have been considered to be harmful in patients with liver disease, and many of the prescribing information labels consider them to be contraindicated in patients with active liver disease. However, recent studies have shown the contrary, warranting further investigation and discussion. This review aims to describe the latest literature on the mechanism, safety profile and potential benefits of statins use on the natural history of chronic liver disease (CLD) progression and its complications. RECENT FINDINGS A number of recently published studies have added to the existing body of literature supporting the concept that statins are safe and likely to be beneficial for treating patients with CLD. Patients with CLD including hepatitis B virus infection, hepatitis C virus infection, nonalcoholic fatty liver disease and alcohol on statins have been shown to have a lower rate of decompensating events, lower incidence of hepatocellular cancer, a lower rate of infections, and increased survival. However, the majority of the available literature supporting statin use in patients with liver disease comes from retrospective observational studies with high potential for bias. SUMMARY Statins appear to be safe in patients with compensated cirrhosis, and evidence suggests that they may reduce fibrosis, even in patients with advanced fibrosis and cirrhosis. Further high-quality research on this topic is needed to fully delineate the effect of statins in patients with liver disease.
📖 Papers frequently viewed together
7 Citations
2 Citations
111 Citations
References78
Newest
#1Don C. Rockey (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
#1Don C. Rockey (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 12
Last. Scott L. Friedman (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 142
view all 2 authors...
Abstract Hepatitis C virus (HCV) infection and its complications have been the major cause of cirrhosis and its complications for several decades in the Western world. Until recently, treatment for HCV with interferon-based regimens was associated with moderate success but was difficult to tolerate. More recently, however, an arsenal of novel and highly effective direct acting antiviral (DAA) drugs has transformed the landscape by curing HCV in a broad range of patients, including those with est...
1 CitationsSource
#1Vlad Ratziu (University of Paris)H-Index: 64
#2Scott L. Friedman (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 142
16 CitationsSource
#1Songling Liu (MUSC: Medical University of South Carolina)H-Index: 10
#2Louis M. Luttrell (MUSC: Medical University of South Carolina)H-Index: 80
Last. Don C. Rockey (MUSC: Medical University of South Carolina)H-Index: 75
view all 4 authors...
Endothelial cell nitric oxide (NO) synthase (eNOS), the enzyme responsible for synthesis of NO in endothelial cells, is regulated by complex posttranslational mechanisms. Sinusoidal portal hypertension, a disorder characterized by liver sinusoidal endothelial cell (SEC) injury with resultant reduced eNOS activity and NO production within the liver, has been associated with defects in eNOS protein–protein interactions and posttranslational modifications. We and others have previously identified n...
7 CitationsSource
#1Yue Gu (JLU: Jilin University)H-Index: 1
#2Yang Xueqin (JLU: Jilin University)H-Index: 1
Last. Li Deli (JLU: Jilin University)H-Index: 1
view all 4 authors...
Statin has been more and more widely used in chronic liver disease, however, existed studies have attained contradictory results. According to the present study, we aimed to test the efficacy and safety of statin via a meta-analysis. Different databases were searched for full-text publication based on inclusion and exclusion criteria. For data-pooling, fixed-effect model was applied if heterogeneity wasn’t detected. Otherwise, random-effect model was adopted. Heterogeneity was detected by I squi...
6 CitationsSource
#1Miren Bravo (Autonomous University of Barcelona)H-Index: 4
#2Imma Raurell (Autonomous University of Barcelona)H-Index: 11
Last. María Martell (Autonomous University of Barcelona)H-Index: 22
view all 10 authors...
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function imp...
9 CitationsSource
#1Barbra A. Dickerman (Harvard University)H-Index: 12
#2Xabier García-Albéniz (Harvard University)H-Index: 23
Last. Miguel A. Hernán (MIT: Massachusetts Institute of Technology)H-Index: 107
view all 5 authors...
The increasing availability of large healthcare databases is fueling an intense debate on whether real-world data should play a role in the assessment of the benefit–risk of medical treatments. In many observational studies, for example, statin users were found to have a substantially lower risk of cancer than in meta-analyses of randomized trials. Although such discrepancies are often attributed to a lack of randomization in the observational studies, they might be explained by flaws that can b...
49 CitationsSource
#1Tracey G. Simon (Harvard University)H-Index: 20
#2Ann-Sofi Duberg (Örebro University)H-Index: 20
Last. Jonas F. Ludvigsson (Columbia University)H-Index: 81
view all 8 authors...
Background: Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.Objective: To assess the relationship between ...
22 CitationsSource
#1Fabio NascimbeniH-Index: 25
#2E. PellegriniH-Index: 7
Last. Amedeo LonardoH-Index: 66
view all 8 authors...
Abstract Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of alcohol-like hepatic histological changes, which occur in the absence of any competing causes of chronic liver disease, notably including significant alcohol consumption. A close and bi-directional relationship links NAFLD with the metabolic syndrome (MetS), and concurrent MetS will hasten the progression to more severe forms of NAFLD, including cirrhosis and hepatocellular carcinoma (HCC). Patients with NAFLD will typical...
24 CitationsSource
#1Yung Lee (McMaster University)H-Index: 11
#2Aristithes G. Doumouras (McMaster University)H-Index: 13
Last. Dennis Hong (McMaster University)H-Index: 14
view all 8 authors...
Background & Aims Bariatric surgery has been reported to lead to complete resolution of nonalcoholic fatty liver disease (NAFLD) following the sustained weight loss induced in obese patients. We performed a systematic review and meta-analysis to evaluate the effects of bariatric surgery on NAFLD in obese patients. Methods We searched MEDLINE, EMBASE, CENTRAL, and Web of Science databases through May 2018 for studies that compared liver biopsy results before and after bariatric surgery in obese p...
81 CitationsSource
#1David E. Kaplan (HUP: Hospital of the University of Pennsylvania)H-Index: 71
#2Marina Serper (HUP: Hospital of the University of Pennsylvania)H-Index: 21
Last. Tamar H. TaddeiH-Index: 20
view all 11 authors...
Background & Aims Concerns related to hepatotoxicity frequently lead to discontinuation or non-initiation of 3-hydroxy-3-methylglutaryl–coenzyme A reductase therapy in patients with cirrhosis despite data supporting statin use. We investigated the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma development in a large national cohort of patients with cirrhosis. Methods We performed a retrospective cohort study of patient...
32 CitationsSource
Cited By0
Newest